Symbols / CAPR Stock $27.96 +7.33% Capricor Therapeutics, Inc.

Healthcare • Biotechnology • United States • NMS
CAPR (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Linda Marbán Ph.D.
Exch · Country NMS · United States
Market Cap 1.62B
Enterprise Value 1.24B
Income -114.59M
Sales —
FCF (ttm) -70.47M
Book/sh 4.83
Cash/sh 4.81
Employees 231
Insider 10d —
IPO Feb 13, 2007
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout —
P/E —
Forward P/E -36.61
PEG 0.38
P/S —
P/B 5.79
P/C —
EV/EBITDA -10.56
EV/Sales —
Quick Ratio 8.28
Current Ratio 8.42
Debt/Eq 5.30
LT Debt/Eq —
EPS (ttm) -2.32
EPS next Y -0.76
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-11
Earnings (prior) 2026-03-12
ROA -31.23%
ROE -56.40%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 57.91M
Shs Float 48.55M
Insider Own 9.47%
Instit Own 59.72%
Short Float 21.11%
Short Ratio 10.34
Short Interest 11.07M
52W High 40.37
vs 52W High -30.74%
52W Low 4.30
vs 52W Low 550.23%
Beta 0.37
Impl. Vol. 1.33%
Rel Volume 0.67
Avg Volume 1.08M
Volume 719.99K
Target (mean) $54.11
Tgt Median $54.00
Tgt Low $38.00
Tgt High $63.00
# Analysts 9
Recom None
Prev Close $26.05
Price $27.96
Change 7.33%
About

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$54.11
Mean price target
2. Current target
$27.96
Latest analyst target
3. DCF / Fair value
$-21.90
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$27.96
Low
$38.00
High
$63.00
Mean
$54.11

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-13 reit HC Wainwright & Co. Buy → Buy $60
2026-03-13 main B. Riley Securities Buy → Buy $63
2026-03-13 reit Piper Sandler Overweight → Overweight $58
2026-03-13 reit HC Wainwright & Co. Buy → Buy $60
2026-03-10 reit HC Wainwright & Co. Buy → Buy $60
2025-12-15 reit B. Riley Securities Buy → Buy $50
2025-12-10 reit Piper Sandler Overweight → Overweight $45
2025-12-08 main Oppenheimer Outperform → Outperform $54
2025-12-04 main Maxim Group Buy → Buy $50
2025-12-03 main HC Wainwright & Co. Buy → Buy $60
2025-11-12 main Roth Capital Buy → Buy $13
2025-09-25 reit HC Wainwright & Co. Buy → Buy $24
2025-09-11 reit HC Wainwright & Co. Buy → Buy $24
2025-07-14 main Roth Capital Buy → Buy $12
2025-07-11 main HC Wainwright & Co. Buy → Buy $24
2025-06-26 init B. Riley Securities — → Buy $21
2025-06-25 main Jones Trading Buy → Buy $29
2025-06-24 reit HC Wainwright & Co. Buy → Buy $77
2025-06-23 main Oppenheimer Outperform → Outperform $22
2025-06-17 reit Roth Capital Buy → Buy $31
News
RSS: Latest CAPR news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-18 BERGMANN ANTHONY Chief Financial Officer — 3,000 $1.39 $4,170
2026-05-13 LITVACK FRANK I Director — 3,937 $1.39 $5,472
2026-05-01 KRASNEY KAREN General Counsel — 25,000 $31.70 $792,548
2026-05-01 BERGMANN ANTHONY Chief Financial Officer — 25,000 $31.70 $792,540
2026-05-01 KRASNEY KAREN General Counsel — 25,000 $3.18 $79,500
2026-05-01 BERGMANN ANTHONY Chief Financial Officer — 25,000 $3.18 $79,500
2026-04-02 SABAR KARIMAH ES Director — 7,529 $32.00 $240,928
2026-04-02 SABAR KARIMAH ES Director — 7,529 $3.18 $23,942
2026-04-01 SABAR KARIMAH ES Director — 115,000 $30.17 $3,515,468
2026-04-01 SABAR KARIMAH ES Director — 115,000 $4.86 $558,900
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
-100.00%
22.27
-11.55%
25.18
+886.81%
2.55
Operating Revenue
0.00
-100.00%
22.27
-11.55%
25.18
+886.81%
2.55
Operating Expense
108.14
+66.80%
64.83
+31.63%
49.26
+52.74%
32.25
Research And Development
84.45
+69.02%
49.97
+37.10%
36.45
+67.06%
21.82
Selling General And Administration
22.75
+60.05%
14.21
+14.95%
12.37
+19.83%
10.32
General And Administrative Expense
22.75
+60.05%
14.21
+14.95%
12.37
+19.83%
10.32
Salaries And Wages
15.53
+46.44%
10.61
+15.56%
9.18
+32.31%
6.94
Other Gand A
7.22
+100.04%
3.61
+13.20%
3.19
-5.77%
3.38
Total Expenses
108.14
+66.80%
64.83
+31.63%
49.26
+52.74%
32.25
Operating Income
-108.14
-154.07%
-42.56
-76.77%
-24.08
+18.92%
-29.70
Total Operating Income As Reported
-108.14
-154.07%
-42.56
-76.77%
-24.08
+18.92%
-29.70
EBITDA
-100.11
-156.42%
-39.04
-69.67%
-23.01
+21.11%
-29.16
Normalized EBITDA
-106.21
-158.22%
-41.13
-66.31%
-24.73
+16.59%
-29.65
Reconciled Depreciation
1.89
+32.54%
1.43
+33.34%
1.07
+100.49%
0.53
EBIT
-102.00
-152.06%
-40.47
-68.06%
-24.08
+18.92%
-29.70
Total Unusual Items
6.10
+191.84%
2.09
+21.33%
1.72
+253.53%
0.49
Total Unusual Items Excluding Goodwill
6.10
+191.84%
2.09
+21.33%
1.72
+253.53%
0.49
Special Income Charges
-0.16
-39.64%
-0.11
-1767.32%
-0.01
+82.37%
-0.03
Other Special Charges
—
—
—
—
Net Income
-105.04
-159.58%
-40.47
-81.57%
-22.29
+23.20%
-29.02
Pretax Income
-105.04
-159.58%
-40.47
-81.56%
-22.29
+23.20%
-29.02
Net Non Operating Interest Income Expense
-3.05
0.00
—
—
Interest Expense Non Operating
3.05
0.00
—
—
Net Interest Income
-3.05
0.00
—
—
Interest Expense
3.05
0.00
—
—
Other Income Expense
6.15
+192.97%
2.10
+17.17%
1.79
+164.12%
0.68
Other Non Operating Income Expenses
0.05
+507.96%
0.01
-88.96%
0.07
-64.50%
0.19
Gain On Sale Of Security
6.26
+184.05%
2.20
+27.44%
1.73
+231.46%
0.52
Tax Provision
0.00
+0.00%
0.00
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-105.04
-159.58%
-40.47
-81.57%
-22.29
+23.20%
-29.02
Net Income From Continuing Operation Net Minority Interest
-105.04
-159.58%
-40.47
-81.57%
-22.29
+23.20%
-29.02
Net Income From Continuing And Discontinued Operation
-105.04
-159.58%
-40.47
-81.57%
-22.29
+23.20%
-29.02
Net Income Continuous Operations
-105.04
-159.58%
-40.47
-81.57%
-22.29
+23.20%
-29.02
Normalized Income
-111.14
-161.16%
-42.56
-77.25%
-24.01
+18.63%
-29.51
Net Income Common Stockholders
-105.04
-159.58%
-40.47
-81.57%
-22.29
+23.20%
-29.02
Diluted EPS
-2.26
-96.52%
-1.15
-38.55%
-0.83
+29.66%
-1.18
Basic EPS
-2.26
-96.52%
-1.15
-38.55%
-0.83
+29.66%
-1.18
Basic Average Shares
46.48
+31.97%
35.22
+31.52%
26.78
+9.06%
24.55
Diluted Average Shares
46.48
+31.97%
35.22
+31.52%
26.78
+9.06%
24.55
Diluted NI Availto Com Stockholders
-105.04
-159.58%
-40.47
-81.57%
-22.29
+23.20%
-29.02
Depreciation Amortization Depletion Income Statement
0.94
+44.17%
0.65
+47.21%
0.44
+293.04%
0.11
Depreciation And Amortization In Income Statement
0.94
+44.17%
0.65
+47.21%
0.44
+293.04%
0.11
Depreciation Income Statement
—
0.65
+47.21%
0.44
+293.04%
0.11
Gain On Sale Of PPE
-0.16
-39.64%
-0.11
-1767.32%
-0.01
+82.37%
-0.03
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
355.95
+108.79%
170.48
+190.26%
58.73
+17.25%
50.09
Current Assets
322.94
+97.66%
163.39
+221.27%
50.86
+18.58%
42.89
Cash Cash Equivalents And Short Term Investments
318.13
+109.96%
151.52
+283.70%
39.49
-4.67%
41.42
Cash And Cash Equivalents
287.85
+2450.26%
11.29
-23.19%
14.69
+53.02%
9.60
Other Short Term Investments
30.28
-78.41%
140.23
+465.60%
24.79
-22.08%
31.82
Receivables
0.06
-99.43%
10.37
-0.03%
10.37
+1794.15%
0.55
Accounts Receivable
0.06
-99.43%
10.37
-0.03%
10.37
+1794.15%
0.55
Prepaid Assets
—
—
—
—
Other Current Assets
4.75
+216.59%
1.50
+50.73%
1.00
+8.25%
0.92
Total Non Current Assets
33.01
+365.20%
7.10
-9.94%
7.88
+9.33%
7.21
Net PPE
31.85
+363.33%
6.87
-9.68%
7.61
+9.70%
6.94
Gross PPE
37.00
+258.39%
10.32
+5.17%
9.82
+20.90%
8.12
Accumulated Depreciation
-5.15
-49.29%
-3.45
-56.39%
-2.21
-86.70%
-1.18
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.51
+164.82%
0.19
+2.17%
0.19
+34.92%
0.14
Construction In Progress
11.44
0.00
—
—
Other Properties
22.27
+191.84%
7.63
+1.75%
7.50
+13.85%
6.59
Leases
2.79
+11.36%
2.50
+17.48%
2.13
+52.82%
1.39
Goodwill And Other Intangible Assets
—
—
—
—
Other Non Current Assets
1.16
+423.00%
0.22
-17.33%
0.27
+0.00%
0.27
Total Liabilities Net Minority Interest
50.16
+100.48%
25.02
-30.76%
36.13
-5.68%
38.31
Current Liabilities
35.84
+70.44%
21.03
-32.76%
31.27
+32.57%
23.59
Payables And Accrued Expenses
17.21
+110.13%
8.19
+31.06%
6.25
+26.94%
4.92
Payables
1.65
-49.61%
3.28
-47.46%
6.25
+26.94%
4.92
Accounts Payable
1.65
-49.61%
3.28
-47.23%
6.22
+28.71%
4.83
Current Accrued Expenses
15.56
+217.01%
4.91
—
—
Current Debt And Capital Lease Obligation
0.20
-75.76%
0.83
+11.44%
0.75
+9.83%
0.68
Current Capital Lease Obligation
0.20
-75.76%
0.83
+11.44%
0.75
+9.83%
0.68
Current Deferred Liabilities
12.00
+0.00%
12.00
-50.56%
24.27
+34.98%
17.98
Current Deferred Revenue
12.00
+0.00%
12.00
-50.56%
24.27
+34.98%
17.98
Other Current Liabilities
6.42
—
—
—
Total Non Current Liabilities Net Minority Interest
14.32
+258.68%
3.99
-17.90%
4.86
-66.97%
14.72
Long Term Debt And Capital Lease Obligation
14.32
+2223.55%
0.62
-58.55%
1.49
-20.83%
1.88
Long Term Capital Lease Obligation
14.32
+2223.55%
0.62
-58.55%
1.49
-20.83%
1.88
Non Current Deferred Liabilities
—
—
0.00
-100.00%
9.47
Non Current Deferred Revenue
—
—
0.00
-100.00%
9.47
Other Non Current Liabilities
—
3.38
+0.00%
3.38
+0.00%
3.38
Stockholders Equity
305.79
+110.22%
145.46
+543.60%
22.60
+91.76%
11.79
Common Stock Equity
305.79
+110.22%
145.46
+543.60%
22.60
+91.76%
11.79
Capital Stock
0.06
+25.86%
0.05
+46.34%
0.03
+23.40%
0.03
Common Stock
0.06
+25.86%
0.05
+46.34%
0.03
+23.40%
0.03
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
57.37
+25.86%
45.58
+46.34%
31.15
+23.40%
25.24
Ordinary Shares Number
57.37
+25.86%
45.58
+46.34%
31.15
+23.40%
25.24
Additional Paid In Capital
610.33
+77.31%
344.22
+89.44%
181.70
+22.16%
148.74
Retained Earnings
-304.88
-52.57%
-199.83
-25.39%
-159.37
-16.26%
-137.08
Gains Losses Not Affecting Retained Earnings
0.28
-72.43%
1.03
+335.50%
0.24
+124.06%
0.11
Other Equity Adjustments
0.28
-72.43%
1.03
+335.50%
0.24
+124.06%
0.11
Total Equity Gross Minority Interest
305.79
+110.22%
145.46
+543.60%
22.60
+91.76%
11.79
Total Capitalization
305.79
+110.22%
145.46
+543.60%
22.60
+91.76%
11.79
Working Capital
287.10
+101.68%
142.36
+626.85%
19.59
+1.47%
19.30
Invested Capital
305.79
+110.22%
145.46
+543.60%
22.60
+91.76%
11.79
Total Debt
14.52
+900.80%
1.45
-35.10%
2.24
-12.66%
2.56
Capital Lease Obligations
14.52
+900.80%
1.45
-35.10%
2.24
-12.66%
2.56
Net Tangible Assets
305.79
+110.22%
145.46
+543.60%
22.60
+91.76%
11.79
Tangible Book Value
305.79
+110.22%
145.46
+543.60%
22.60
+91.76%
11.79
Dueto Related Parties Current
—
—
0.03
-69.21%
0.09
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-69.81
-74.55%
-40.00
-56.25%
-25.60
-620.61%
4.92
Cash Flow From Continuing Operating Activities
-69.81
-74.55%
-40.00
-56.25%
-25.60
-620.61%
4.92
Net Income From Continuing Operations
-105.04
-159.58%
-40.47
-81.57%
-22.29
+23.20%
-29.02
Depreciation Amortization Depletion
1.89
+32.54%
1.43
+33.34%
1.07
+100.49%
0.53
Depreciation
1.89
+32.54%
1.43
+33.34%
1.07
+100.49%
0.53
Amortization Cash Flow
—
—
—
0.00
Depreciation And Amortization
1.89
+32.54%
1.43
+33.34%
1.07
+100.49%
0.53
Amortization Of Intangibles
—
—
—
0.00
Other Non Cash Items
3.76
+8058.33%
-0.05
-94.63%
-0.02
-115.01%
0.16
Stock Based Compensation
17.23
+76.39%
9.77
+32.10%
7.39
+65.80%
4.46
Asset Impairment Charge
—
—
—
0.00
Operating Gains Losses
0.16
+39.64%
0.11
+1767.32%
0.01
-82.37%
0.03
Gain Loss On Sale Of PPE
0.16
+39.64%
0.11
+1767.32%
0.01
-82.37%
0.03
Change In Working Capital
12.20
+213.12%
-10.78
+8.23%
-11.75
-140.88%
28.75
Change In Receivables
10.31
+294115.81%
0.00
+100.04%
-9.82
-6204.57%
-0.16
Change In Prepaid Assets
-4.09
-792.53%
-0.46
-504.41%
-0.08
-131.61%
0.24
Change In Payables And Accrued Expense
5.98
+208.27%
1.94
+46.35%
1.33
+9.78%
1.21
Change In Payable
—
—
1.33
+9.78%
1.21
Change In Account Payable
—
—
1.33
+9.78%
1.21
Change In Other Working Capital
—
-12.27
-286.10%
-3.18
-111.58%
27.45
Change In Other Current Assets
—
—
0.00
-100.00%
0.01
Change In Other Current Liabilities
—
—
—
—
Investing Cash Flow
97.48
+183.90%
-116.18
-2374.45%
5.11
+114.56%
-35.07
Cash Flow From Continuing Investing Activities
97.48
+183.90%
-116.18
-2374.45%
5.11
+114.56%
-35.07
Net PPE Purchase And Sale
-11.72
-661.82%
-1.54
+24.84%
-2.05
+39.06%
-3.36
Purchase Of PPE
-11.72
-661.82%
-1.54
+24.84%
-2.05
+39.06%
-3.36
Capital Expenditure
-11.72
-661.82%
-1.54
+24.84%
-2.05
+39.06%
-3.36
Net Investment Purchase And Sale
109.20
+195.25%
-114.64
-1702.14%
7.16
+122.56%
-31.71
Purchase Of Investment
-151.39
+27.37%
-208.44
-113.91%
-97.44
+14.69%
-114.22
Sale Of Investment
260.60
+177.83%
93.80
-10.33%
104.60
+26.78%
82.51
Financing Cash Flow
248.89
+62.92%
152.77
+497.23%
25.58
+424.84%
4.87
Cash Flow From Continuing Financing Activities
248.89
+62.92%
152.77
+497.23%
25.58
+424.84%
4.87
Net Issuance Payments Of Debt
—
—
—
—
Issuance Of Debt
—
—
—
—
Long Term Debt Issuance
—
—
—
—
Net Long Term Debt Issuance
—
—
—
—
Net Common Stock Issuance
237.03
+55.61%
152.32
+496.98%
25.52
+431.18%
4.80
Proceeds From Stock Option Exercised
11.86
+2534.18%
0.45
+596.85%
0.06
-8.11%
0.07
Changes In Cash
276.56
+8215.36%
-3.41
-166.93%
5.09
+120.14%
-25.28
Beginning Cash Position
11.29
-23.19%
14.69
+53.02%
9.60
-72.47%
34.89
End Cash Position
287.85
+2450.26%
11.29
-23.19%
14.69
+53.02%
9.60
Free Cash Flow
-81.54
-96.31%
-41.53
-50.25%
-27.64
-1875.58%
1.56
Interest Paid Supplemental Data
0.00
0.00
0.00
0.00
Income Tax Paid Supplemental Data
0.00
+0.00%
0.00
0.00
0.00
Common Stock Issuance
237.03
+55.61%
152.32
+496.98%
25.52
+431.18%
4.80
Issuance Of Capital Stock
237.03
+55.61%
152.32
+496.98%
25.52
+431.18%
4.80
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category